Literature DB >> 9438701

Future directions in esophageal cancer.

J D Luketich1, P Schauer, K Urso, E Kassis, P Ferson, R Keenan, R Landreneau.   

Abstract

The incidence of esophageal cancer in the United States has been increasing in recent years. Since multimodality therapy for esophageal cancer has produced discouraging results, recent approaches have focused on molecular biological techniques, positron emission tomography, and minimally invasive surgery to improve pretreatment staging which will facilitate a more accurate assessment of new treatment. This article summarizes the results of studies investigating these approaches and outlines the strategy currently used at the University of Pittsburgh Medical Center.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9438701     DOI: 10.1378/chest.113.1_supplement.120s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

Review 1.  Multimodality therapy for gastroesophageal cancers.

Authors:  Kenneth K Wang
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

Review 2.  The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment.

Authors:  Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

3.  Minimally invasive surgical staging for esophageal cancer.

Authors:  J D Luketich; M Meehan; N T Nguyen; N Christie; T Weigel; S Yousem; R J Keenan; P R Schauer
Journal:  Surg Endosc       Date:  2000-08       Impact factor: 4.584

4.  Minimally invasive esophagectomy: outcomes in 222 patients.

Authors:  James D Luketich; Miguel Alvelo-Rivera; Percival O Buenaventura; Neil A Christie; James S McCaughan; Virginia R Litle; Philip R Schauer; John M Close; Hiran C Fernando
Journal:  Ann Surg       Date:  2003-10       Impact factor: 12.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.